| Synonym |
| Thai / English name |
Part Used : ใบActivity : P-GLYCOPROTEIN INHIBITIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with a single oral dose of GBE 120 mgDuration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: A single oral dose of GBE did not affect the pharmacokinetics of talinolol. Primary constituents of ginkgo include flavonoids were reported to be substrates and modulators of P-glycoprotein. Further studies are required to identify whether quercetin and kaempferol are active substances in GBE to inhibit P-glycoprotein in humans.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
Part Used : ใบActivity : P-GLYCOPROTEIN INHIBITIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : 21-27 yearsRoute : Oral administrationDose/Conc.(herb) : Talinolol 100 mg with after 14 days of repeated GBE ingestion (360 mg/day)Duration : 24 hoursType of interaction : PharmacokineticsInteraction with drug : TalinololDose/Conc.(drug) : -Result : NegativeRemark : Result: Repeated ingestion of GBE increased the talinolol maximum plasma concentration (C max) by 36% (90% Cl 10-68; p=0.025), the area under the concentration-time curve (AUC)0-24-by 26% (90% Cl 11-43; p=0.008) and AUC0-infinity by 22% (90% Cl 8-37; p=0.014), respectively, without significant changes in elimination half-life and the tin to Cmax.Note : - The pharmacokinetics of oral talinolol were determined after administration of a 100 mg tablet of talinolol at 24 hours in a 3-stage sequential study. The first tablet of talinolol was given on day 1 of the study. The second tablet was taken on day 8 with a single oral dose of a GBE 120 mg tablet. On days 9 through 22, same dose of a GBE was ingested by each subject 3 time daily. The final tablet of talinolol was taken on day 23, wtih 44th dose of GBE. - Healthy subjects.
